A Phase II Open-Label Study to Investigate the Effects of CK-1827452 Injection on Ventricular Performance, Myocardial Oxygen Consumption, and Myocardial Efficiency in Patients With Heart Failure and Left Ventricular Systolic Dysfunction.
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2015
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors Cytokinetics
- 18 Dec 2008 Results are expected in 2009.
- 25 Sep 2008 Trial design presented at the Annual Meeting of the Heart Failure Society of America in Sep 2008.
- 05 Sep 2008 Status changed from planning to recruiting.